KRMD KORU Medical Systems, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 704440 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.4%
TTM net income YoY77.8%
TTM EPS YoY92.9%
Revenue 3-yr CAGR17.3%
Net income 3-yr CAGR—
Margins
Gross margin63.6%
Operating margin-1.3%
Net margin-1.8%
FCF margin-0.8%
EBITDA margin0.4%
Returns
ROE-4.6%
ROA-2.9%
ROIC (approx.)-4.7%
Asset turnover1.66x
Leverage & solvency
Liabilities / assets32.6%
Debt / equity0.00x
Current ratio2.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.54x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $41.13M | $33.65M | $28.52M | $27.90M | $23.49M |
| Cost of revenue | $15.52M | $12.31M | $11.81M | $12.53M | $9.72M |
| Gross profit | $25.60M | $21.33M | $16.71M | $15.37M | $13.77M |
| R&D expense | $4.39M | $5.26M | $5.74M | $4.96M | $2.47M |
| SG&A expense | $23.38M | $21.63M | $20.37M | $20.61M | $17.86M |
| Operating income | -$2.97M | -$6.45M | -$10.27M | -$10.78M | -$7.03M |
| Pretax income | -$2.62M | -$6.06M | -$9.77M | -$10.68M | -$6.36M |
| Income tax | $21,890 | $2,893 | $3.97M | -$2.01M | -$1.80M |
| Net income | -$2.64M | -$6.07M | -$13.74M | -$8.66M | -$4.56M |
| EBITDA | -$2.16M | -$5.56M | -$9.40M | -$10.19M | -$6.57M |
| EPS (basic) | -0.06 | -0.13 | -0.30 | -0.19 | -0.10 |
| EPS (diluted) | -0.06 | -0.13 | -0.30 | -0.19 | -0.10 |
| Weighted avg. shares (diluted) | 46.19M | 45.80M | 45.60M | 45.00M | 44.39M |
| Balance sheet | |||||
| Cash & equivalents | $8.87M | $9.58M | $11.48M | $17.41M | $25.33M |
| Receivables | $5.97M | $5.72M | $4.05M | $3.56M | $3.59M |
| Inventory | $3.68M | $2.80M | $3.48M | $6.40M | $6.11M |
| Current assets | $19.99M | $19.13M | $20.26M | $29.80M | $37.32M |
| PP&E, net | $4.47M | $4.29M | $3.84M | $3.89M | $1.11M |
| Intangibles | $684,841 | $730,279 | $754,361 | $787,182 | $808,813 |
| Total assets | $28.20M | $27.22M | $28.46M | $42.33M | $41.29M |
| Current liabilities | $8.19M | $7.20M | $4.45M | $6.96M | $4.79M |
| Total liabilities | $11.15M | $10.40M | $8.11M | $11.01M | $4.79M |
| Shareholders' equity | $17.05M | $16.81M | $20.35M | $31.33M | $36.50M |
| Shares outstanding | 46.37M | 45.96M | 45.67M | 45.44M | 44.62M |
| Cash flow statement | |||||
| Operating cash flow | $462,405 | -$319,718 | -$4.89M | -$5.40M | -$4.32M |
| Capital expenditure | $932,517 | $1.30M | $782,949 | $2.76M | $346,178 |
| Free cash flow | -$470,112 | -$1.62M | -$5.68M | -$8.17M | -$4.67M |
| Investing cash flow | -$949,790 | -$1.33M | -$814,597 | -$2.80M | -$366,169 |
| Financing cash flow | -$221,350 | -$248,533 | -$218,867 | $279,485 | $2.71M |
| Depreciation & amortization | $810,500 | $888,473 | $870,390 | $587,137 | $463,130 |
| Stock-based compensation | $2.71M | $2.62M | $2.77M | $3.08M | $2.71M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.